AIM To study the influential factors in patients with congestive heart failure blood stasis on clinical pharmacokinetics of digoxin. METHODS Patients with congestive heart failure blood stasis were divided into two groups according to blood stasis degree and heart function. The first group (heart function Ⅰ～Ⅱ) included 34 cases with light blood stasis, while the second group (heart function Ⅲ～Ⅳ) included 38 cases with serious blood stasis. Patients of both groups were administered digoxin tables 0.125～0.385 mg*d-1 orally. Fluorescence Polarization Immunoassay (FPIA) was used to measure serum steady state digoxin concentrations, the method of one point of Bayesian to calculate digoxin clinical pharmacokinetics parameters, and the pharmacokinetics parameters of two groups were compared statistically. RESULTS With the aggravation of blood stasis and heart function damage, the Vd and CL of digoxin decreased markedly, but AUC of digoxin increased significantly. CONCLUSION The pharmacokinetics parameters are different in patients with different degrees of blood stasis in congestive heart failure, and the kidney function decrease is one of the major causes of this difference.%目的 研究充血性心力衰竭（congestive heart failure, CHF）血瘀证对地高辛药代动力学的影响. 方法 将充血性心力衰竭血瘀证患者按血瘀程度及心功能状况分为两组，第1组34例，血瘀较轻，心功能为Ⅰ～Ⅱ级，第2组38例，血瘀较重，心功能为Ⅲ～Ⅳ级，两组患者均口服地高辛片0.125～0.385 mg*d-1，用荧光偏振酶标免疫法检测地高辛的稳态血药浓度，同时以苦味酸法测定血清肌酐，用Bayesian一点法拟合地高辛的个体药动学参数，统计学比较两组患者地高辛药动学参数间差异. 结果 随着血瘀及心功能损伤的加重，地高辛的分布容积显著减少，清除率显著下降，AUC显著提高，血清中肌酐显著增高. 结论 地高辛在不同程度充血性心力衰竭血瘀证患者体内的药代动力学存在差异，肾功能衰减是造成差异的主要原因之一.
展开▼
